Medicare to Begin Covering Weight-Loss Drugs Including Wegovy Starting July 1

1-Minute Brief

Expanded Medicare coverage may increase access to weight-loss medications for older Americans and impact healthcare costs and insurance practices.

Key Facts

• Starting July 1, Medicare beneficiaries will have access to weight-loss drugs for the first time.
• Novo Nordisk is preparing for the CMS bridge program and educating providers on patient eligibility.
• Employers and health plans have been reluctant to cover the cost of weight-loss medications.
• Medicare beneficiaries are advised to consider unique factors regarding the new coverage.
• Novo Nordisk has been advocating for broader insurance coverage of its weight-loss medications.

What Happened

Medicare will begin covering weight-loss drugs, including Wegovy, starting July 1. Novo Nordisk is preparing for the rollout and working to inform healthcare providers about eligibility.

Why It Matters

This change could increase access to obesity treatments for millions of older Americans and may influence broader insurance coverage policies for weight-loss medications.

What's Next

It remains to be seen whether patient demand will surge immediately or grow gradually after July 1. Ongoing education efforts for providers and pharmacists are underway.